News And Articles

Dry eyes can become a serious medical concern resulting in major quality of life concerns and, in severe cases, partial or full loss of vision. New research using Bioss antibodies indicates a potential new therapy for dry eyes, which is now in phase 3 clinical trials in the U.S.

Through a proprietary process, Bioss engineers antibodies using short peptide antigens for greater selectivity and ideal detection. Read about our process and the advantages over native protein antigens.

Learn the process of double staining for immunofluorescence and the advantages and disadvantages of using different antibodies for the procedure

Bioss recently surveyed nearly 200 researchers as part of our State of Science report. Our respondents reported high levels of job satisfaction across all specialties and research roles.

Are women scientists leading the political charge? We surveyed nearly 200 researchers from across the U.S. and found women more engaged politically than their male peers. For more data and information, download the full report.

New research into CTE in humans is using an interesting animal model -- woodpeckers. By examining the brains of museum specimens, Boston University researchers are attempting to determine if woodpecker behaviors can lead to the same symptoms and physiology as human CTE patients.